Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease
© 2019 International Parkinson and Movement Disorder Society..
BACKGROUND: Parkinson's disease (PD) is the most common movement disorder among adults, affecting 2% of the world population older than 65 years of age. No diagnostic biomarker for routine use in clinical settings currently exists. Dysregulation of microRNAs (miRNAs) has been implicated in various neurodegenerative conditions, including PD. Distinct miRNAs have been demonstrated to be involved in the regulation of α-synuclein, a key player in PD pathogenesis; miR-153 and miR-223 are downregulated in the brain and serum of parkinsonian GFAP.HMOX1 transgenic mice where they directly regulate α-synuclein.
OBJECTIVE: To ascertain whether salivary miR-153 and miR-223 are similarly downmodulated in, and may serve as diagnostic biomarkers of, idiopathic PD.
METHODS: Using reverse transcriptase quantitative polymerase chain reaction, miR-153 and miR-223 levels were evaluated in the saliva of 77 non-neurological controls and 83 PD patients. Levels of heme oxygenase-1 and α-synuclein were measured using enzyme-linked immunosorbent assay. Analyses were adjusted by age, sex, medication exposure, disease duration, and relevant comorbidities.
RESULTS: Log-transformed expression levels of miR-153 and miR-223 were significantly decreased in the saliva of human PD patients in comparison with nonneurological controls. The miRNA expression levels did not change as a function of disease progression (Hoehn and Yahr staging). The area under the receiver operating characteristic curve separating controls from PD patients was 79% (95% confidence interval, 61%-96%) for miR-153 and 77% (95% confidence interval, 59%-95%) for miR-223. The ratios of miRNAs to oligomeric α-synuclein, total α-synuclein, or heme oxygenase-1 protein did not improve accuracy of the test.
CONCLUSION: Salivary miR-153 and miR-223 levels may serve as useful, noninvasive, and relatively inexpensive diagnostic biomarkers of idiopathic PD. © 2019 International Parkinson and Movement Disorder Society.
| Errataetall: |
CommentIn: Nat Rev Neurol. 2020 Feb;16(2):65. - PMID 31853098 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Movement disorders : official journal of the Movement Disorder Society - 35(2020), 3 vom: 16. März, Seite 468-477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cressatti, Marisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-synuclein |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 31.05.2022 published: Print-Electronic CommentIn: Nat Rev Neurol. 2020 Feb;16(2):65. - PMID 31853098 Citation Status MEDLINE |
|---|
| doi: |
10.1002/mds.27935 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304019089 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304019089 | ||
| 003 | DE-627 | ||
| 005 | 20231225114055.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mds.27935 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1013.xml |
| 035 | |a (DE-627)NLM304019089 | ||
| 035 | |a (NLM)31800144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cressatti, Marisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Neurol. 2020 Feb;16(2):65. - PMID 31853098 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 International Parkinson and Movement Disorder Society. | ||
| 520 | |a BACKGROUND: Parkinson's disease (PD) is the most common movement disorder among adults, affecting 2% of the world population older than 65 years of age. No diagnostic biomarker for routine use in clinical settings currently exists. Dysregulation of microRNAs (miRNAs) has been implicated in various neurodegenerative conditions, including PD. Distinct miRNAs have been demonstrated to be involved in the regulation of α-synuclein, a key player in PD pathogenesis; miR-153 and miR-223 are downregulated in the brain and serum of parkinsonian GFAP.HMOX1 transgenic mice where they directly regulate α-synuclein | ||
| 520 | |a OBJECTIVE: To ascertain whether salivary miR-153 and miR-223 are similarly downmodulated in, and may serve as diagnostic biomarkers of, idiopathic PD | ||
| 520 | |a METHODS: Using reverse transcriptase quantitative polymerase chain reaction, miR-153 and miR-223 levels were evaluated in the saliva of 77 non-neurological controls and 83 PD patients. Levels of heme oxygenase-1 and α-synuclein were measured using enzyme-linked immunosorbent assay. Analyses were adjusted by age, sex, medication exposure, disease duration, and relevant comorbidities | ||
| 520 | |a RESULTS: Log-transformed expression levels of miR-153 and miR-223 were significantly decreased in the saliva of human PD patients in comparison with nonneurological controls. The miRNA expression levels did not change as a function of disease progression (Hoehn and Yahr staging). The area under the receiver operating characteristic curve separating controls from PD patients was 79% (95% confidence interval, 61%-96%) for miR-153 and 77% (95% confidence interval, 59%-95%) for miR-223. The ratios of miRNAs to oligomeric α-synuclein, total α-synuclein, or heme oxygenase-1 protein did not improve accuracy of the test | ||
| 520 | |a CONCLUSION: Salivary miR-153 and miR-223 levels may serve as useful, noninvasive, and relatively inexpensive diagnostic biomarkers of idiopathic PD. © 2019 International Parkinson and Movement Disorder Society | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Heme oxygenase-1 | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a microRNA | |
| 650 | 4 | |a saliva | |
| 650 | 4 | |a α-synuclein | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a MIRN153 microRNA, human |2 NLM | |
| 650 | 7 | |a MIRN223 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a alpha-Synuclein |2 NLM | |
| 700 | 1 | |a Juwara, Lamin |e verfasserin |4 aut | |
| 700 | 1 | |a Galindez, Julia M |e verfasserin |4 aut | |
| 700 | 1 | |a Velly, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Nkurunziza, Eva S |e verfasserin |4 aut | |
| 700 | 1 | |a Marier, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Canie, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Gornistky, Mervyn |e verfasserin |4 aut | |
| 700 | 1 | |a Schipper, Hyman M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Movement disorders : official journal of the Movement Disorder Society |d 1995 |g 35(2020), 3 vom: 16. März, Seite 468-477 |w (DE-627)NLM012945846 |x 1531-8257 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:3 |g day:16 |g month:03 |g pages:468-477 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mds.27935 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 3 |b 16 |c 03 |h 468-477 | ||